Search Results - brian+law

1 Results Sort By:
Anticancer Agents for Triple-Negative Breast Cancers
Selectively Kills EGFR+, HER2+, and HER+3 Tumors via New Mechanism, Enabling These Tumors to Overcome Resistance to Current TherapyThis first-in-class compound selectively kills cancer cells without harming normal tissues. The Epidermal Growth Factor Receptor (EGFR) family members -- EGFR, Human Epidermal Growth Factor Receptor-2 (HER2) and Human Epidermal...
Published: 11/19/2021   |   Inventor(s): Brian Law, Ronald Castellano
Keywords(s): Akt, breast cancer, Compound, EGFR, Her2, HER2/neu receptor, Therapeutic
Category(s): Technology Classifications > Human Health Care > Therapeutics